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Introduction: 
 
Aneurysmal subarachnoid haemorrhage can 
be complicated by acute hyponatraemia in 
neurosurgical patients. De Oliveira Manoel et 
al., (2016, p. 1) define aneurysmal subarach-
noid haemorrhage (SAH) as ‘a complex neu-
rovascular syndrome with profound systemic 
effects and is associated with high disability 
and mortality’.  An aneurysmal SAH is the 
result of cerebral aneurysm rupture or trau-
ma, thus resulting in bleeding in the sub-
arachnoid space. Rupture of cerebral aneu-
rysms commonly occurs at bifurcations and 
branches within the Circle of Willis (Hickey 
2014).  
 
 
 
 
 
 
 
 
Patients with a SAH commonly develop hy-
ponatraemia within two weeks of cerebral 
rupture (Vrsajkov, Javanovic, Stanisavljevic, 
Uvelin, & Vrsajkov, 2012).  Hyponatraemia is 
the most common electrolyte abnormality to 
develop in patients with a SAH. It is defined 
by Hickey (2014, p. 203) as ‘serum sodium 
less than 135mEq/L’. High-grade SAH pa-
tients with anterior circulation aneurysms 
have a 50% incident rate of developing acute 
hyponatraemia (De Oliveira Manoel et al., 
2016), yet the pathophysiology linking SAH 
and hyponatraemia is not fully understood 
(De Oliveira Manoel et al., 2016; Manza-
nares, Aramendi, Langlois & Biestro, 2014; 
Mapa et al., 2016; See, Wu, Lai, Gross, & 
Du, 2016).  
 
This enquiry into practice focuses on the 
treatment and management of hypo-
natraemia in SAH patients using hypertonic 
saline, with a structured discussion and anal-
ysis of current evidence based practice. The 
following will be explored; importance of a 
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high standard of care, a review of local policy 
relevant to SAH and hyponatraemia manage-
ment and the impact on future nursing prac-
tices including a need for increased educa-
tion. For this paper, the hospital has been de-
identified, the reviewed policy is from a large 
metropolitan hospital with a 32 - bed ward 
with twelve dedicated neurosurgical beds 
including a 4 - bed neurosurgery high de-
pendency unit (HDU).  
 
Pathophysiology of SAH and hypo-
natraemia: 
 
According to See et al. (2016) 30% of SAH 
patients develop hyponatraemia 1-week post 
rupture. Hannon et al., (2014) report 56% of 
patients admitted with SAH will develop hy-
ponatraemia during their hospital admission. 
Due to the significant percentage of patients 
that develop hyponatraemia post rupture, 
these patients are at high risk for deteriora-
tion. It is crucial to observe for complications 
and symptoms associated with both SAH and 
hyponatraemia, with care provided being in 
accordance to current evidence based prac-
tice and local hospital policies. Hypo-
natraemia can occur in patients with a SAH 
due to syndrome of inappropriate anti-diuretic 
hormone (SIADH), cerebral salt wasting 
(CSW), glucocorticoid insufficiency and ex-
cessive use of diuretics (Hannon et al., 2014; 
Saramma, Menon, Srivastava & Sarma, 
2013; See et al., 2016; Walcott, Kahle & 
Simard, 2012).  According to Vrsajkov et al., 
(2012) & Mapa et al., (2016) the location of 
the aneurysm could potentially influence the 
patient’s risk of developing hyponatraemia as 
aneurysms that rupture within the anterior 
circulation can affect the hypothalamic-
pituitary region of the brain, consequently 
resulting in SIADH or CSW. SAH can lead to 
either an increase in secretion of antidiuretic 
hormone (ADH) causing SIADH or CSW due 
to the enhanced release of atrial natriuretic 
peptide, brain natriuretic peptide and nora-
drenaline. SIADH and CSW are fundamental-
ly different conditions that can be difficult for 
clinicians to differentiate in regards to treat-
ment (De Oliveria Manoel et al., 2016). It is 
crucial to initiate treatment targeted to the 
correct aetiology to ensure serum sodium 
levels are corrected appropriately; with a 
treatment plan reflective of the clinical situa-
tion and consideration of potential adverse 
effects (Ball & Iqbal, 2015; Hannon et al., 
2014). Hyponatraemia can be life threatening 
if incorrectly treated and managed.  
 
Intracellular and extracellular osmolarity must 
be equal. If there is a low serum sodium lev-
el, cells will begin to swell as fluid moves 
from the extracellular compartment to the 
interstitial fluid, resulting in intracellular oede-
ma due to changes in osmolarity. When hy-
ponatraemia develops rapidly the brain can 
be slow to adapt to the hypotonic environ-
ment (Mapa et al., 2016; Spasovski et al., 
2014; Verbalis et al., 2013). When low serum 
sodium levels are over corrected too rapidly it 
can cause blood brain barrier breakdown and 
injury to myelin in the central nervous sys-
tem, precipitating osmotic demyelination syn-
drome (Ball & Iqbal, 2015; Sterns, Hix & Sil-
ver, 2010; Verbalis et al,. 2013). Acute symp-
tomatic hyponatraemia secondary to a SAH 
can have severe complications, with symp-
toms including cerebral oedema, seizures 
and cerebrovascular spasm (Saramma et al., 
2013).  Patient outcomes can vary signifi-
cantly from a full recovery to severe disability 
or death post SAH, depending on severity of 
the bleed and associated complications (De 
Oliveira Manoel et al., 2016).  
 
Nurses must accurately assess patients for 
changes in Glasgow Coma Scale (GCS) 
score and neurological condition. Whilst con-
currently observing for signs and symptoms 
related to acute hyponatraemia including 
headache, nausea and vomiting, the nurse 
must be aware that the patient’s condition 
can rapidly deteriorate leading to confusion, 
seizures, respiratory arrest and severe cere-
bral oedema resulting in death (Rafat et al., 
2014; Verbalis et al., 2013).  
 
TABLE 1: Serum sodium levels 
This table lists serum sodium ranges of hypo-
natraemia and associated symptoms (Stern, 
2015).   
 
 
Treatment of hyponatraemia:   
 
Treatment and management of acute hypo-
natraemia in SAH patients should comply 
with hospital local policies, in conjunction with 
global evidence-based practice. The local 
policy at this hospital for ‘IV infusion of hyper-
tonic saline for hyponatraemia management’ 
Hyponatraemia Serum so-
dium range 
Symptoms 
Mild  
hyponatraemia 
130-135 
mmol/L 
Nausea, vomiting, short
-term memory loss & 
dizziness. 
Moderate  
hyponatraemia 
121-129 
mmol/L 
Confusion, muscle 
weakness, generalised 
malaise & headaches. 
Severe  
hyponatraemia 
<120  
mmol/L 
Lethargy, agitation, 
increased ICP, respira-
tory depression, cere-
bral oedema & disori-
entation. 
Australasian Journal of Neuroscience  Volume 27 ● Number 2 ● Oct 2017 
 3 
has recently been reviewed and updated 
based on current evidence-based journal arti-
cles. Although medical professionals are pre-
scribing the treatment, it is nurses administer-
ing the medication therefore it is paramount 
nurses administering hypertonic saline for 
severe hyponatraemia have sufficient 
knowledge and understanding of the high-risk 
infusion. According to See et al., (2016) the 
proportion of patients that developed hypo-
natraemia post clipping or coiling of an aneu-
rysm, was almost equal. Hannon et al., 
(2014) also reiterated there was no difference 
in the incidence of hyponatraemia based on 
patients that had an aneurysm clipping or 
endovascular coiling. It is understood hypo-
natraemia may develop in response to hypo-
thalamic injury as a result of SAH, conse-
quently leading to aforementioned complica-
tions (Dority & Oldham, 2016; Vrsajkov et al., 
2012). Due to increased renal reabsorption of 
free water in SIADH, fluid restriction is con-
sidered the gold standard of treatment. How-
ever, treatment of SIADH with fluid restriction 
in the setting of SAH is contraindicated and 
potentially detrimental to patient outcomes 
due to the increased risk of hypovolaemia-
associated cerebral infarct and worsening 
vasospasm (De Oliveira Manoel et al., 2016; 
Hickey, 2014; Manzanares et al., 2014; Sa-
ramma et al., 2013; Walcott et al., 2012).  
Management of hyponatraemia in patients 
with a SAH includes preventing hypovolae-
mia and administration of isotonic fluid to pre-
vent onset or exacerbation of cerebral oede-
ma (De Oliveira Manoel et al., 2016; Raya & 
Diringer, 2014). 
 
Hypertonic Saline:  
 
The local hospital policy recommends for 
acute symptomatic hyponatraemia, an IV 3% 
hypertonic saline bolus of 100-250ml over 10
-20 minutes to correct low serum sodium lev-
els, aiming for a sodium increase of 5mmol/L. 
The bolus can be repeated twice at 10-
minute intervals if serum sodium remains 
unchanged (Adrogue & Madias, 2012; Ver-
balis et al., 2013; Grant et al., 2015; Spasov-
ski et al., 2014). Starke & Dumont (2014) dis-
cuss the effects of hypertonic saline, due to 
its ability to move fluid from the interstitial and 
intracellular spaces via osmotic gradient into 
the intravascular system, thus reducing asso-
ciated symptoms.  The administration of hy-
pertonic saline in SAH patients has been 
shown to increase arterial blood pressure, 
cerebral perfusion pressure and flow velocity 
whilst simultaneously reducing intracranial 
pressure and cerebral oedema (Starke & 
Dumont, 2014; Thongrong et al., 2014; Wal-
cott et al., 2012). It is crucial to re-check se-
rum sodium levels and urine osmolarity sim-
ultaneously post IV bolus and then repeat 2-4 
hours post administration. To ensure accu-
rate interpretation of values urine osmolarity 
and bloods should be taken at the same time 
(Spasovski et al., 2014). According to 
Adrogue & Madias (2012) 2-4 hourly neuro-
logical observations including GCS and vital 
signs should be performed, as well as serum 
sodium and urine electrolytes post-hypertonic 
saline administration, to ensure rapid over-
correction has not occurred. As per the re-
viewed hospital policy, patients administered 
with hypertonic saline require continuous car-
diac monitoring and pulse oximetry in the 
HDU. In addition, an indwelling urinary cathe-
ter is inserted for accurate fluid balance due 
to the potential for large diuresis and this en-
sures the ability to obtain frequent urine os-
molarity samples. Due to the high risks asso-
ciated with hypertonic saline administration 
for SAH patients with severe symptomatic 
hyponatraemia, patients should not be left 
unattended whilst receiving the IV infusion. It 
can be observed that hospital policies are 
medical based, and can often lack guidance 
towards nursing practice and responsibilities.  
This signifies the need for policy change in 
conjunction with further nursing education for 
managing acute symptomatic hyponatraemia 
patients.  
 
Hypertonic saline indications, infusion rates 
and target sodium concentrations have been 
described by Spasovski et al., (2014) as un-
clear, which can be challenging for nurses 
when prescribed and administered to pa-
tients. Currently there are no consensus 
guidelines for optimal concentration, infusion 
rates and dose. This is debated both in Aus-
tralia and internationally regarding the admin-
istration and dosage of hypertonic saline for 
acute hyponatraemia, and remains an ongo-
ing area of research due to inconsistencies in 
clinical recommendations. However evidence
-based clinical practice guidelines are utilised 
to provide recommendations for clinically ap-
propriate treatment and pathology testing 
(Nagler et al., 2014; Starke & Dumont, 2014; 
Thongrong et al., 2014). A review of current 
evidence-based practice at this hospital indi-
cated that this local policy is in compliance 
with research findings, where a senior neuro-
surgical registrar decides rate and dosage for 
SAH patients.  
 
Despite hypertonic saline improving symp-
toms associated with hyponatraemia and 
raising sodium levels, it can result in side ef-
fects including hypernatraemia, hypokalae-
mia and acute renal failure (Manzanares et 
al., 2014). It is important nurses administer-
ing hypertonic saline are aware of these side 
effects especially to observe for hyper-
natraemia, as rapid changes in serum sodi-
um can have detrimental and permanent 
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neurological effects on the patient. Hence, 
serum sodium should not rise more than 
10mmol/L within 24 hours and 18mmol/L 
within 48 hours to prevent osmotic demye-
lination syndrome (Ball & Iqbal, 2015; Grant 
et al., 2015; Rafat et al., 2014; Sood, Sterns, 
Hix, Silver, & Chen, 2013). Osmotic demye-
lination syndrome typically occurs 2-7 days 
post treatment and is clinically characterised 
by irreversible neurological damage (Sood et 
al., 2013). Manzanares et al., (2014, p. 236) 
reports, ‘…in SAH, triple H therapy 
(hypertension, hypovolaemia and haemodilu-
tion) as an anti-vasospasm strategy pro-
motes natriuresis and the risk of hypo-
natraemia’. Thus reiterating the contraindica-
tion of fluid restricting SAH patients, as 
hypovolaemia and a negative fluid balance 
will worsen patient outcomes. Therefore uti-
lising 3% hypertonic saline is the preferred 
treatment (Dority & Oldham, 2016).  
 
Impact on future nursing practice: 
 
It is imperative for nurses and clinicians to 
reflect upon current practices, challenge 
nursing interventions and management. Re-
flecting on current hyponatraemia manage-
ment ensures the care provided to patients is 
based on current published research, whilst 
continuing to have a diagnostic approach in 
regards to accurate interpretation of serum 
sodium values.  It was observed by 
McKeever et al., (2016, p. 85) that, ‘delivering 
evidence-based nursing care contributes to 
improved patient outcomes, a superior quality 
of care, and potential cost efficiencies’.  Nurs-
es can feel empowered and engaged when 
given the opportunity to contribute to im-
provements in nursing care and future prac-
tices within their speciality area, therefore 
improving the quality of care provided to pa-
tients.  Although the local neurosurgery policy 
reflects current evidence based practices, 
there is a need for further nursing education. 
This is due to the infusion being high risk and 
may not be commonly administered in HDU 
settings, rather in the Intensive Care Unit. 
Increasing education will ensure nurses car-
ing for SAH patients whom are at risk of de-
veloping hyponatraemia have a comprehen-
sive knowledge of the condition, appropriate 
treatment as well as identifying signs and 
symptoms of deterioration. In conjunction, 
awareness of the risk factors of osmotic de-
myelination syndrome when administering 
hypertonic saline, such as malnutrition, liver 
disease and hypokalaemia (Rafat et al., 
2014). Hyponatraemia can often lead to in-
creased length of hospital stay, increased 
costs and associated complications, conse-
quently highlighting the need for close moni-
toring of sodium levels and implementing ap-
propriate treatment to reduce morbidity and 
mortality (Ball & Iqbal, 2015; Hannon et al., 
2014; See et al., 2016). Increased knowledge 
of risk factors associated with SAH and hypo-
natraemia include advanced age, smoking, re
-bleeding and cerebral vasospasm. This 
knowledge may prove to be vital in monitor-
ing for sodium changes post – rupture in pa-
tients with pre-existing risk factors (Saramma 
et al., 2013).   
 
Conclusion: 
 
In conclusion, enquiry into practice is vital in 
continuing to develop and improve upon pro-
fessional nursing practice whilst maintaining 
a high standard of evidence-based care.  The 
incidence of SAH patients developing hypo-
natraemia is 50%, illustrating the importance 
of close monitoring of serum sodium concen-
trations and associated symptoms. Neurosur-
gical patients that become hyponatraemic 
during inpatient admission can result in in-
creased length of hospital stay, increased 
morbidity and mortality, signifying the im-
portance of monitoring serum sodium levels 
promptly, as well as for prevention of clinical 
consequences that can occur with untreated 
acute symptomatic hyponatraemia, such as 
cerebral oedema and increased intracranial 
pressure.  
 
It can be concluded the reviewed local hospi-
tal policy for the monitoring, management 
and treatment of acute symptomatic hypo-
natraemia with administration of 3% hyper-
tonic saline is in accord with current evidence 
based practice and global standard of care.  
However currently there remains a lack of 
consensus regarding the dosage and infusion 
rate of hypertonic saline, thus referring to 
clinical practice guidelines for recommenda-
tions in regards to treatment and manage-
ment with SAH patients. Therefore to im-
prove upon future local practice, increased 
nursing education is needed to be able to 
identify and determine signs and symptoms 
associated with hyponatraemia, monitoring 
for changes in serum sodium levels and in a 
timely manner escalating this to medical 
teams for appropriate intervention that is re-
flective of the clinical situation. Reflection into 
clinical practices and local policies proves 
invaluable to patient outcomes.  
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